Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(7):1044–1048. doi: 10.1038/bjc.1997.178

Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin's disease.

C Rubio 1, M E Hill 1, S Milan 1, M E O'Brien 1, D Cunningham 1
PMCID: PMC2222758  PMID: 9083341

Abstract

The risk of idiopathic pneumonia syndrome (IPS) in patients with Hodgkin's disease (HD) undergoing high-dose chemotherapy (HDC) is significant, and once developed IPS is potentially fatal. The aim of this study was to quantify this risk accurately and determine prognostic factors for its development and course. Using a computerized database, all patients with HD treated with BCNU (carmustine) containing HDC and haematopoietic support at The Royal Marsden between November 1985 and March 1994 were identified. Patient characteristics, previous treatments, disease status at HDC, dose of BCNU, incidence and severity of IPS and survival were all determined and analysed. During the study period, 94 patients received HDC, of whom 26 (28%) had a first episode of IPS within a year of HDC and 23 within 6 months. The median time to presentation after HDC was 93 days (range 12-336 days). The only factors that significantly increased the risk of developing IPS on multivariate analysis were dose of BCNU (P for trend = 0.03) and female sex (P = 0.04). Of these 26 patients, 14 had complete resolution of all symptoms, three had persisting pulmonary symptoms at 6 months and the remaining nine died of IPS at a median of 74 days (19-418 days). All the patients who died from IPS had the first symptoms within 6 months of HDC and all received doses of BCNU > 475 mg m(-2) (P for trend = 0.001). For women receiving > 475 mg m(-2) the risk of death was significantly higher than for men (P = 0.035) but not for those receiving < 475 mg m(-2). Previous lung disease, persisting residual disease before HDC, previous bleomycin or previous mantle radiotherapy did not increase either the incidence of IPS or risk of a fatal outcome. We conclude that the main avoidable risk factor for fatal IPS after HDC is dose of BCNU, and this is especially true for women. If < 475 mg m(-2) is given, even patients with previous mantle radiotherapy and/or previous bleomycin have a very low risk of developing fatal lung toxicity if lung function tests are normal.

Full text

PDF
1044

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmed T. Autologous marrow transplantation for Hodgkin's disease current techniques and prospects. Cancer Invest. 1990;8(1):99–106. doi: 10.3109/07357909009017551. [DOI] [PubMed] [Google Scholar]
  2. Aronin P. A., Mahaley M. S., Jr, Rudnick S. A., Dudka L., Donohue J. F., Selker R. G., Moore P. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. N Engl J Med. 1980 Jul 24;303(4):183–188. doi: 10.1056/NEJM198007243030403. [DOI] [PubMed] [Google Scholar]
  3. Arrick B. A., Nathan C. F. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res. 1984 Oct;44(10):4224–4232. [PubMed] [Google Scholar]
  4. Bierman P. J., Bagin R. G., Jagannath S., Vose J. M., Spitzer G., Kessinger A., Dicke K. A., Armitage J. O. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann Oncol. 1993 Nov;4(9):767–773. doi: 10.1093/oxfordjournals.annonc.a058662. [DOI] [PubMed] [Google Scholar]
  5. Clark J. G., Hansen J. A., Hertz M. I., Parkman R., Jensen L., Peavy H. H. NHLBI workshop summary. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis. 1993 Jun;147(6 Pt 1):1601–1606. doi: 10.1164/ajrccm/147.6_Pt_1.1601. [DOI] [PubMed] [Google Scholar]
  6. Durant J. R., Norgard M. J., Murad T. M., Bartolucci A. A., Langford K. H. Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU). Ann Intern Med. 1979 Feb;90(2):191–194. doi: 10.7326/0003-4819-90-2-191. [DOI] [PubMed] [Google Scholar]
  7. Goldstone A. H., McMillan A. K. The place of high-dose therapy with haemopoietic stem cell transplantation in relapsed and refractory Hodgkin's disease. Ann Oncol. 1993;4 (Suppl 1):21–27. doi: 10.1093/annonc/4.suppl_1.s21. [DOI] [PubMed] [Google Scholar]
  8. Jones R. J., Piantadosi S., Mann R. B., Ambinder R. F., Seifter E. J., Vriesendorp H. M., Abeloff M. D., Burns W. H., May W. S., Rowley S. D. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol. 1990 Mar;8(3):527–537. doi: 10.1200/JCO.1990.8.3.527. [DOI] [PubMed] [Google Scholar]
  9. Kreisman H., Wolkove N. Pulmonary toxicity of antineoplastic therapy. Semin Oncol. 1992 Oct;19(5):508–520. [PubMed] [Google Scholar]
  10. Litam J. P., Dail D. H., Spitzer G., Vellekoop L., Verma D. S., Zander A. R., Dicke K. A. Early pulmonary toxicity after administration of high-dose BCNU. Cancer Treat Rep. 1981 Jan-Feb;65(1-2):39–44. [PubMed] [Google Scholar]
  11. Lund M. B., Kongerud J., Boe J., Nome O., Abrahamsen A. F., Ihlen H., Forfang K. Cardiopulmonary sequelae after treatment for Hodgkin's disease: increased risk in females? Ann Oncol. 1996 Mar;7(3):257–264. doi: 10.1093/oxfordjournals.annonc.a010569. [DOI] [PubMed] [Google Scholar]
  12. Millard F. C., Nakielny R. A., Makris M., Winfield D. A. The chest radiograph appearances seen following high dose chemotherapy and autologous bone marrow transplantation for resistant malignant lymphoma. Br J Radiol. 1991 Feb;64(758):103–106. doi: 10.1259/0007-1285-64-758-103. [DOI] [PubMed] [Google Scholar]
  13. Miller C. B., Piantadosi S., Vogelsang G. B., Marcellus D. C., Grochow L., Kennedy M. J., Jones R. J. Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant. J Clin Oncol. 1996 Apr;14(4):1327–1332. doi: 10.1200/JCO.1996.14.4.1327. [DOI] [PubMed] [Google Scholar]
  14. O'Brien M. E., Milan S., Cunningham D., Jones A. L., Nicolson M., Selby P., Hickish T., Hill M., Gore M. E., Viner C. High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index. Br J Cancer. 1996 May;73(10):1272–1277. doi: 10.1038/bjc.1996.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pecego R., Hill R., Appelbaum F. R., Amos D., Buckner C. D., Fefer A., Thomas E. D. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation. 1986 Nov;42(5):515–517. doi: 10.1097/00007890-198611000-00015. [DOI] [PubMed] [Google Scholar]
  16. Phillips G. L., Fay J. W., Herzig G. P., Herzig R. H., Weiner R. S., Wolff S. N., Lazarus H. M., Karanes C., Ross W. E., Kramer B. S. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study. Cancer. 1983 Nov 15;52(10):1792–1802. doi: 10.1002/1097-0142(19831115)52:10<1792::aid-cncr2820521006>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  17. Reece D. E., Barnett M. J., Connors J. M., Fairey R. N., Fay J. W., Greer J. P., Herzig G. P., Herzig R. H., Klingemann H. G., LeMaistre C. F. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol. 1991 Oct;9(10):1871–1879. doi: 10.1200/JCO.1991.9.10.1871. [DOI] [PubMed] [Google Scholar]
  18. Weaver C. H., Appelbaum F. R., Petersen F. B., Clift R., Singer J., Press O., Bensinger W., Bianco J., Martin P., Anasetti C. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J Clin Oncol. 1993 Jul;11(7):1329–1335. doi: 10.1200/JCO.1993.11.7.1329. [DOI] [PubMed] [Google Scholar]
  19. Wheeler C., Antin J. H., Churchill W. H., Come S. E., Smith B. R., Bubley G. J., Rosenthal D. S., Rappaport J. M., Ault K. A., Schnipper L. E. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol. 1990 Apr;8(4):648–656. doi: 10.1200/JCO.1990.8.4.648. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES